Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


A Randomized Controlled Trial of the N-methyl-D-aspartate (NMDA) Receptor Antagonist Ketamine in Comorbid Depression and Alcohol Dependence.


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT01551329

Organisation Name: Yale University

Overal Status: Completed

Start Date: March 2012

Last Update: March 9, 2020

Lead Sponsor: Yale University

Brief Summary: The purpose of this study is to evaluate the efficacy of ketamine in reducing depressive symptoms in subjects with a comorbid major depressive episode and alcohol dependence. The investigators hypothesize the following for the present study:

A single dose of ketamine will induce a rapid, robust and sustained reduction in depressive symptoms in subjects with a comorbid major depressive episode and alcohol dependence relative to placebo as defined by change in Hamilton Depression Rating Scale total scores at 72 hours post infusion.

A single dose of ketamine can be delivered safely, with minimal adverse events or complications, in subjects with a comorbid major depressive episode and alcohol dependence.

Conditions:
  • Depression
  • Alcohol Dependence


Total execution time in seconds: 0.18175387382507